Physician profile
Thomas B Day
NPI 1336112622
$3,568.52
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $251 · 2021: $1,802 · 2022: $536 · 2023: $603 · 2024: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $699 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $698.51 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medimetriks Pharmaceuticals, INC. | $1,530.70 | 2020-2024 | Neo-Synalar, Clindacin Etz |
| Regeneron Healthcare Solutions, INC. | $475.97 | 2019-2023 | Dupixent |
| Novartis Pharmaceuticals Corporation | $180.18 | 2019-2023 | |
| Incyte Corporation | $173.03 | 2021-2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $156.69 | 2022-2023 | Sotyktu |
| Amgen INC. | $154.42 | 2020-2022 | |
| Abbvie INC. | $130.30 | 2021-2023 | Rinvoq |
| Sanofi-Aventis U.S. LLC | $129.98 | 2021-2023 | |
| Leo Pharma INC. | $100.60 | 2021-2023 | Adbry |
| Sun Pharmaceutical Industries INC. | $66.58 | 2019-2021 | |
| Genzyme Corporation | $56.01 | 2023-2024 | |
| Vyne Pharmaceuticals INC. | $53.00 | 2020 | |
| Ucb, INC. | $51.25 | 2021-2022 | |
| Lilly USA, LLC | $50.37 | 2022-2023 | Taltz |
| Dermavant Sciences, INC. | $43.67 | 2023-2024 | Vtama |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $38.16 | 2022 | |
| Janssen Biotech, INC. | $36.67 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $35.57 | 2023-2024 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.08 | 2019-2020 | |
| Almirall LLC | $28.17 | 2019-2021 | |
| Journey Medical Corporation | $16.54 | 2022 | |
| Galderma Laboratories, L.P. | $14.43 | 2024 | |
| Dermira, INC. | $12.15 | 2021 | |
| Glenmark Therapeutics INC. | $5.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.